Effectiveness and safety of proton pump inhibitors for treating acute pancreatitis

Abstract

Background: Previous studies have showed that anti-acid therapy with proton pump inhibitors (PPIs) can inhibit pancreatic secretion and it may be used in treating acute pancreatitis (AP). But at present, there is no systematic reviews for the evidence and the therapeutic effectiveness and safety of anti-acid therapy with PPIs in AP were not unclear. Therefore, we will undertake a systematic review of the literature to summarize previous evidence regarding this topic, in order to clarify the effectiveness and safety of anti-acid therapy with PPIs in AP. Methods: We will search the EMBASE, WANFANG DATA, Web of Knowledge, China National Knowledge Infrastructure, PubMed, ClinicalTrials.gov and Cochrane Library from inception to June 30,2021 to retrieve relevant studies using the search strategy: (“Proton pump inhibitors” OR “PPI” OR “PPIs” OR “Omeprazole” OR “Tenatoprazole” OR “Pantoprazole” OR “acid suppression therapy” OR “acid suppression drugs”) AND (“pancreatitis” OR “pancreatitides”). Two authors independently judged study eligibility and extracted data. Heterogeneity will be examined by computing the Q statistic and I2 statistic. Results: This study assessed the efficiency and safety of proton pump inhibitors for treating acute pancreatitis. Conclusions: This study will provide reliable evidence-based evidence for the clinical application of PPIs for treating AP. Ethics and dissemination: Ethical approval is unnecessary as this protocol is only for systematic review and does not involve privacy data. The findings of this study will be disseminated electronically through a peer-review publication or presented at a relevant conference.

Influence of the Microbiome Metagenomics and Epigenomics on Gastric Cancer

“…Accumulating evidence shows that prolonged use of proton pump inhibitors (PPIs) increase the risk of developing GC [162][163][164]. The PPIs are generally used to treat acid reflux related disorders, GERD, peptic ulcers, Zollinger-Ellison syndrome (ZES), pancreatitis, and esophagitis [165][166][167]. Most of the above-mentioned diseases are RFs of GC, thus supporting the potential link between prolonged use of these drugs and their contribution to GC carcinogenesis.…”

Features of Medical Correction of Chronic Pancreatitis With Gastric Hyperacidality Syndrome and Obesity

“…This approach helps to reduce the autolysis of the parenchyma of the organ and the severity of enzyme intoxication, suppression of hyperenzymemia, reduce the risk of systemic complications of pancreatitis, steatosis of the pancreas and liver [6], even associated atherosclerotic complications [7], creating favorable conditions for the regeneration of pancreatic tissue, correction of metabolic disorders [8]. The use of proton pump inhibitors (PPIs) reduces the exocrine function of the pancreas, the production of pancreatic enzymes by inhibiting gastric secretion [9]. Today, the issue of "night breakthrough" of acidity and night fluctuations in application continues to be controversial.…”